CAPRICOR THERAPEUTICS, INC. (CAPR): Results of Operations and Financial Condition
CAPRICOR THERAPEUTICS, INC. (CAPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update ● Deramiocel Biologics License Application (BLA) under active FDA review ● HOPE-3 Phase 3 results published in The Lancet; primary endpoint of upper limb function achiev
How this was made
The 30-second read
Why it matters
Deramiocel’s FDA review remains active, but the FDA advisory committee voted 3 in favor and 9 against on substantial evidence of effectiveness for the requested cardiomyopathy indication. The company simultaneously points to HOPE-3’s published primary endpoint significance (PUL 2.0, p=0.029) and says the primary endpoint was unaffected by a statistical-model correction, while noting only left ventricular ejection fraction changed.
Market read
Traders get a decision-relevant regulatory snapshot: advisory committee outcome, endpoint-level HOPE-3 publication details including a statistical-model correction, and cash runway plus BIMO inspection status.
What to watch
The filing notes a BIMO Form 483 observation and a statistical-model issue that affected only left ventricular ejection fraction; traders may be over-weighting the 3-9 vote versus the specific endpoint-level outcomes and FDA’s independent review.
Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
The company reported no revenue and a wider net loss as operating expenses increased, while Deramiocel remains under FDA review following an advisory committee vote of 3 in favor and 9 against for cardiomyopathy in DMD. Cash, cash equivalents and marketable securities totaled $237,934,782, and management stated that available financial resources are sufficient for at least the next twelve months.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenueGAAP | — | – | – |
| Research and developmentGAAP | 28,866,292 | – | – |
| General and administrativeGAAP | 14,079,328 | – | – |
| Total operating expensesGAAP | 42,945,620 | – | – |
| Loss from operationsGAAP | (42,945,620) | – | – |
| Other incomeGAAP | 2,271 | – | – |
| Investment incomeGAAP | 2,211,295 | – | – |
| Total other income (expense)GAAP | 2,213,566 | – | – |
| Loss before income taxesGAAP | (40,732,054) | – | – |
| Provision for income taxesGAAP | (1,600) | – | – |
| Net lossGAAP | $ (40,733,654) | – | – |
| Net loss per share, basic and dilutedGAAP | $ (0.70) | – | – |
| Weighted average number of shares, basic and dilutedGAAP | 57,926,347 | – | – |
| Net unrealized gain (loss) on marketable securitiesGAAP | 90,186 | – | – |
| Comprehensive lossGAAP | $ (40,643,468) | – | – |
| Cash, cash equivalents and marketable securitiesother | $ 237,934,782 | – | – |
| Total assetsother | $ 368,735,835 | – | – |
| Total liabilitiesother | $ 122,516,945 | – | – |
| Total stockholders’ equityother | 246,218,890 | – | – |
at least the next twelve months outlook
- NoteThe Company believes that, based on its current operating plan and financial resources, its available cash, cash equivalents and marketable securities are sufficient to fund its operating capital requirements for at least the next twelve months.
- NoteThis outlook excludes any potential revenue from product sales, the potential monetization of a Priority Review Voucher, if received, or other non-operating sources of capital.
- NoteThe Company expects to provide additional guidance on its longer-term financial outlook following greater regulatory clarity, which will inform future strategic and capital allocation decisions.
What drove it
- Deramiocel BLA remains under active FDA review.
- The full HOPE-3 Phase 3 dataset was published in The Lancet in July.
- Deramiocel demonstrated a statistically significant slowing of upper limb disease progression as measured by PUL 2.0 (p=0.029).
- The Company's GMP manufacturing facility in San Diego is operational and positioned to support an initial commercial launch, if Deramiocel is approved.
- Capricor has initiated regulatory engagement in Europe and Japan for Deramiocel.
Concerns
- On July 29, 2026, the Cellular, Tissue and Gene Therapies Advisory Committee voted 3 in favor and 9 against on whether available evidence provides substantial evidence of effectiveness of Deramiocel for the treatment of cardiomyopathy in patients with DMD.
- The FDA conducted a BIMO inspection in July 2026 and issued a Form 483 citing one observation; the Company is awaiting feedback after submitting its responses.
- Capricor identified an issue with the statistical model in the clinical study report and reverted to the statistical analysis plan in place prior to unblinding.
- Programs not directly related to Deramiocel, including the Company's exosome-based platform, are on hold pending further regulatory clarity.
- Capricor is advancing commercial readiness at a slower pace pending regulatory clarity.
- The Company continues to seek rescission in its dispute with NS Pharma and estimates arbitration to begin this fall.
What to watch
- Further FDA updates on the Deramiocel BLA review.
- FDA feedback on the Form 483 observation from the July 2026 BIMO inspection.
- The FDA action on Deramiocel and the resulting impact on commercial-readiness spending, longer-term financial guidance and capital allocation decisions.
- Progress of arbitration with NS Pharma, which the Company estimates will begin this fall.
- Full validation and FDA inspection of the second-floor manufacturing expansion targeted for 2027.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities totaled approximately $237.9 million as of June 30, 2026, compared to approximately $318.1 million as of December 31, 2025.
- Total assets were $ 368,735,835 as of June 30, 2026.
- Total liabilities were $ 122,516,945 as of June 30, 2026.
- Total stockholders’ equity was 246,218,890 as of June 30, 2026.
Analysis
Capricor remained pre-revenue in the second quarter, with total revenue reported as —. The quarterly GAAP net loss was $ (40,733,654), compared with $ (25,910,791) in the prior-year period, as total operating expenses increased to 42,945,620 from 27,717,534. Research and development was 28,866,292, while general and administrative expense was 14,079,328. Investment income of 2,211,295 partially offset the operating loss.
The operating-spend increase was concentrated in both research and development and general and administrative expense. The company had no product revenue and did not report gross margin, operating cash flow, free cash flow, debt, share repurchases, or dividends. Cash, cash equivalents and marketable securities were $ 237,934,782 at June 30, 2026, versus $ 318,128,915 at December 31, 2025. Total liabilities were $ 122,516,945 and total stockholders’ equity was 246,218,890.
The central corporate issue is the Deramiocel BLA review. The FDA advisory committee voted 3 in favor and 9 against on substantial evidence of effectiveness for cardiomyopathy in DMD. Management emphasized that the committee was not asked to vote on the HOPE-3 primary endpoint or overall benefit-risk. HOPE-3 was published in The Lancet, and the company reported statistical significance for upper limb disease progression measured by PUL 2.0 at p=0.029. The company also disclosed a BIMO Form 483 with one observation and said it is awaiting FDA feedback after submitting responses.
The reported clinical-data update includes a revision to left ventricular ejection fraction after the company identified a statistical-model issue and reverted to the pre-unblinding statistical analysis plan. The company said the affected endpoint yields p=0.09 and a 1.8 percentage point treatment difference, compared with topline p=0.04 and a 2.4 percentage point difference. It stated that the pre-specified cardiomyopathy subgroup was unchanged at p=0.02 and that the HOPE-3 primary endpoint was unaffected.
Management is preserving operating flexibility pending regulatory clarity. The San Diego GMP facility is operational, but commercial readiness is proceeding at a slower pace, and non-Deramiocel programs, including the exosome-based platform, are on hold. Management stated that available cash, cash equivalents and marketable securities are sufficient to fund operating capital requirements for at least the next twelve months, excluding potential product sales, monetization of a Priority Review Voucher, if received, and other non-operating capital sources. The next material developments are FDA review progress, BIMO inspection feedback, the FDA action, and the planned arbitration with NS Pharma.
Management, verbatim
Our priority is, and always has been, to get Deramiocel to the patients and families living with Duchenne who need it most
Linda Marbán, Ph.D., Chief Executive Officer of Capricor
The Advisory Committee outcome was not the one we hoped for.
Linda Marbán, Ph.D., Chief Executive Officer of Capricor
We are continuing to work with the Agency on a path forward.
Linda Marbán, Ph.D., Chief Executive Officer of Capricor
Not in the filing
stated, not guessed- Segment revenue and segment comparisons
- GAAP gross profit and gross margin
- Non-GAAP revenue, earnings, operating income, net income, EPS, or margin measures
- Prior-quarter financial results for the second-quarter income-statement metrics
- Percentage year-over-year and quarter-over-quarter changes for reported financial metrics
- Operating cash flow
- Free cash flow
- Debt
- Share repurchases
- Dividends
- Forward revenue guidance
- Forward gross-margin guidance
- Forward operating-expense guidance
- Forward tax-rate guidance
- Longer-term financial guidance
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC 8-K (Item 2.02) with Q2 2026 financial results and a corporate update tied to Deramiocel’s FDA BLA review for Duchenne cardiomyopathy.
Ticker impact
Capricor filed an 8-K with Q2 results plus a Deramiocel FDA BLA update, including a 3-9 advisory vote against cardiomyopathy effectiveness.
Choppy-to-down bias is likely into the next FDA regulatory milestones, with volatility driven by how the FDA weighs the advisory vote versus the published HOPE-3 primary endpoint and secondary cardiac findings.
The filing is a primary disclosure (8-K) and includes multiple decision-relevant items: advisory committee outcome, HOPE-3 publication details, and ongoing FDA review status. However, the recommendation is advisory and non-binding, and the company frames a path forward, limiting directional certainty.
Market effects
Highlights ongoing FDA scrutiny and statistical-model sensitivity in rare-disease cell therapy submissions, which can affect sentiment for similar Duchenne and gene/cell programs.
Limited direct regional spillover; primarily impacts US-listed biotech risk appetite.
HOPE-3 publication in The Lancet and planned Europe/Japan regulatory engagement can influence global rare-disease investor sentiment, but the immediate catalyst is US FDA review.
Counterpoint
The advisory committee was not asked to vote on the HOPE-3 primary endpoint, and the company reports the primary endpoint remained unaffected, suggesting the FDA may still find a viable approval path.
Key entities
- issuerCapricor Therapeutics, Inc.
NASDAQ-listed biotech company developing Deramiocel for Duchenne and related rare diseases; filed Q2 results and regulatory/corporate updates.
- product_candidateDeramiocel
Cell/exosome-based therapy under FDA BLA review; central to the advisory committee outcome and HOPE-3 dataset discussion.
- regulator_advisory_bodyFDA Cellular, Tissue and Gene Therapies Advisory Committee
Voted 3 in favor and 9 against on substantial evidence of effectiveness for Deramiocel in DMD cardiomyopathy.
- clinical_programHOPE-3
Phase 3 study whose full dataset was published in The Lancet; primary endpoint achieved with p=0.029.
- counterpartyNS Pharma
Involved in a US distribution agreement dispute; Capricor withdrew a preliminary injunction motion and expects arbitration to begin this fall.
